A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • STATUS
    Recruiting
  • End date
    Dec 30, 2030
  • participants needed
    1012
  • sponsor
    Clovis Oncology, Inc.
Updated on 4 November 2020
Investigator
Clovis Oncology Clinical Trial Information
Primary Contact
Northern Cancer Institute St Leonards (4.8 mi away) Contact
+178 other location
cancer
rucaparib
ovarian cancer
fallopian tube
platinum-based chemotherapy
peritoneal cancer
cytoreductive surgery

Summary

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Details
Treatment Nivolumab, rucaparib, Placebo Oral Tablet, Placebo IV Infusion
Clinical Study IdentifierNCT03522246
SponsorClovis Oncology, Inc.
Last Modified on4 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet